^
Association details:
| Biomarker: | KMT2A rearrangement |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
601 Venetoclax Plus Decitabine for Young Adults with Newly Diagnosed ELN Adverse-Risk Acute Myeloid Leukemia: Updated Results of a Phase 2 Trial
Published date:
11/03/2022
Excerpt:
This multicenter, single-arm, phase 2 trial (NCT04752527) enrolled young pts (aged between 18 and 59) with ND AML...The CRc rates in pts with 11q23/KMT2A rearrangements and complex karyotype were 66.7% and 88.9%, respectively.
Secondary therapy:
decitabine
DOI:
https://doi.org/10.1182/blood-2022-166384
Trial ID:
